Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 14, 2019; 25(34): 5197-5209
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5197
Table 1 Patient characteristics
CharacteristicPatients (n = 72)
Sex, n (%)
Male52 (72.2)
Female20 (27.8)
Age [yr, median (range)]59.5 (18-82)
BMI (kg/m2, mean ± SD)23.8 ± 3.4
Symptoms, n (%)
Hematochezia37 (51.4)
Abdominal pain23 (31.9)
Changes in bowel habits23 (31.9)
Obstruction12 (16.7)
Abdominal distention5 (9.6)
Weight loss3 (4.2)
Anemia2 (2.8)
Carcinoid syndrome0
Asymptomatic2 (2.8)
Family history of cancer, n (%)
Yes11 (15.3)
No60 (83.3)
Unrecorded1 (1.4)
History of colorectal polyps, n (%)
Yes24 (33.3)
No27 (37.5)
Unrecorded21 (29.2)
Smoking history, n (%)
Yes28 (38.9)
No42 (58.3)
Unrecorded2 (2.8)
Drinking history, n (%)
Yes24 (33.3)
No45 (62.5)
Unrecorded3 (4.2)
Primary sites, n (%)
Rectum46 (63.9)
Rectosigmoid junction2 (2.8)
Sigmoid5 (6.9)
Descending colon4 (5.6)
Transverse colon2 (2.8)
Ascending colon9 (12.5)
Cecum4 (5.6)
Distance of tumor from the anal verge [(for rectal carcinoma, n = 46), n (%)]
0-5 cm28 (60.9)
5-10 cm14 (19.4)
10-15 cm2 (2.8)
Unrecorded2 (2.8)
Tumor size [median (range), cm]5.0 (1.0-15.0)
Tumor stage, n (%)
I4 (5.6)
II4 (5.6)
III27 (37.5)
IV37 (51.4)
Site of distant metastases, n (%)
Liver27 (37.5)
Liver only12 (16.6)
Distant lymph nodes15 (20.8)
Peritoneum5 (6.9)
Bone5 (6.9)
Lung1 (1.4)
Pancreas1 (1.4)
Increase of pretreatment blood LDH, n (%)
Yes10 (13.9)
No29 (40.3)
Unrecorded33 (45.8)